Daniel is a biochemist, entrepreneur, and world-renowned expert in de novo protein design. Daniel completed his undergraduate degree and Ph.D. at UNAM (Mexico), has authored multiple peer-reviewed publications in high-impact journals and is an inventor on several patents. Among his accomplishments, he was the main architect behind NL-201, the first de novo protein to reach clinical trials.

Alfredo graduated in Bioengineering from the UW IPD under David Baker's mentorship. His research focuses on de novo protein design of conditionally-active protein systems that can address challenges in immunotherapy and diagnostics. He has authored multiple scientific publications in high-impact peer-reviewed journals and has published numerous patents describing his inventions.